"HI-Bio was really the key catalyst to bring us back to California," a Biogen executive said of its new South San Francisco ...

A California judge has ruled that Biogen owes Roche $124 million in royalties for its use of intellectual property developed more than 40 years ago by the Swiss company’s subsidiary Genentech that ...

"Countries no longer compete on the basis of low-cost labor; they compete on brain power,” says Biogen CEO Chris Viehbacher ...

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as a ...